metricas
covid
Annals of Hepatology CHOLANGIOCARCINOMA IN INDIVIDUALS WITH CHRONIC LIVER DISEASE IS DIAGNOSED EARLIE...
Journal Information
Vol. 30. Issue S2.
Abstracts of the 2025 Annual Meeting of the ALEH
(September 2025)
Vol. 30. Issue S2.
Abstracts of the 2025 Annual Meeting of the ALEH
(September 2025)
#95
Full text access
CHOLANGIOCARCINOMA IN INDIVIDUALS WITH CHRONIC LIVER DISEASE IS DIAGNOSED EARLIER, LEADING TO BETTER PROGNOSIS
Visits
269
Laura Izquierdo Sanchez1, Julen Matin Robles1, Jone Narbaiza1, Angela Lamarca2, Adelaida La Casta1, Heinz-Josef Klümpen3, Arun Valsan4, Stephanie Roessler5, Chiara Braconi6, Leonardo G. da Fonseca7, Cristina Dopazo8, Trine Folseraas9, Bas Groot Koerkamp10, Domingo Balderramo11, Mariano Ponz Sarvise12, Javier Díaz Ferrer13, Krzysztof Zieniewicz14, Zeno Sparchez15, Kirsten Utpatel16, Markus Peck Radosavljevic17..., Alejandro Forner18, Luis Bujanda1, Jesus M. Banales1Ver más
1 Department of Liver and Gastrointestinal Diseases. Biodonostia Health Research Institute. Donostia University Hospital. University of the Basque Country (UPV/EHU), España.
2 Department of Medical Oncology. The Christie NHS Foundation Trust/Institute of Cancer Sciences. University of Manchester, UK.
3 Department of Medical Oncology. Amsterdam UMC. University of Amsterdam. Cancer Center Amsterdam, Netherlands.
4 Department of Hepatology and Gastroenterology. Amrita Institute of Medical Sciences and Research (AIMS), India.
5 Institute of Pathology. Heidelberg University. Liver Cancer Center Heidelberg (LCCH), Alemania.
6 Institute of Cancer Sciences. University of Glasgow, UK.
7 Instituto do Cancer do Estado de Sao Paulo (ICESP). Hospital das Clinicas (HCFMUSP). Faculdade de Medicina. Universidade de Sao Paulo, Brasil.
8 Department of Hepatic and Biliary Surgery and Transplants. Vall d'Hebron Barcelona Hospital Campus, España.
9 Norwegian PSC Research Center. Department of Transplantation Medicine. Oslo University. Hospital Rikshospitalet, Norway.
10 Department of Surgery. Erasmus MC Cancer Institute. University Medical Center Rotterdam, Netherlands.
11 Gastroenterology Department. Hospital Privado Universitario de Córdoba. Instituto Universitario de Ciencias Biomédicas de Córdoba, Argentina.
12 Clinica Universidad de Navarra and Program in Solid Tumors (CIMA). Universidad de Navarra. IDISNA, España.
13 Departamento del Aparato Digestivo. Hospital Nacional Edgardo Rebagliati Martins-Essalud. Facultad de Medicina. Universidad De San Martin De Porres, Perú.
14 Department of General, Transplant and Liver Surgery. Medical University of Warsaw, Poland.
15 3rd Medical Department. Institute for Gastroenterology and Hepatology. University of Medicine and Pharmacy, Romania.
16 Institute of Pathology. University of Regensburg, Germany.
17 Internal Medicine and Gastroenterology (IMuG) and Emergency Medicine (ZAE). Klinikum Klagenfurt Am Wörtherse, Austria.
18 Liver Unit. Barcelona Clinic Liver Cancer (BCLC) group. Hospital Clinic Barcelona. IDIBAPS. University of Barcelona, España.
Ver más
This item has received
Article information
Abstract
Full Text
Download PDF
Statistics
Special issue
This article is part of special issue:
Vol. 30. Issue S2

Abstracts of the 2025 Annual Meeting of the ALEH

More info
Introduction and Objectives

Cholangiocarcinoma (CCA) incidence and mortality are rising globally. Chronic liver diseases (CLD) are recognized risk factors. This study aimed to compare the clinical presentation and outcomes of CCA in patients with and without CLD, using data from the International CCA Registry.

Patients and Methods

The international CCA Registry is a multicenter observational study enrolling cases from 54 centers across Latin America, Europe, and Asia (2010–2024).

Results

Among 3,693 patients enrolled, 916 had CLD and 2,777 did not. Common CLD conditions were fatty liver disease, cirrhosis, viral hepatitis, and primary sclerosing cholangitis. Compared to non-CLD patients, those with CLD were more often male (69% vs. 53%), younger at diagnosis (63 vs. 66 years), and had higher rates of metabolic risk factors, alcohol use, and smoking. Intrahepatic CCA was more frequent in CLD patients (64% vs. 43%), whereas distal CCA was more common in non-CLD cases (20% vs. 9%). CLD patients had better performance status (ECOG 0: 53% vs. 35%), lower CA19-9 levels (59.0 vs. 134.5 U/mL), and more localized disease (56% vs. 48%). Curative-intent surgery was more frequent in the CLD group (59% vs. 48%), translating into longer median overall survival (12.3 vs. 11.0 months) and higher 5-year survival (OR = 1.67; p < 0.001). The benefit was especially evident in intrahepatic CCA. Treatment responses were comparable between groups.

Conclusions

CCA is diagnosed at earlier stages in individuals with CLD, likely due to certain clinical surveillance, leading to better prognosis. Prospective validation and standardized surveillance protocols are warrant.

Full Text

Conflict of interest: None

Download PDF
Article options
Tools